DATE: July 1, 2016

TO: All New York State Licensed Article 28 Hospitals, New York State Department of Health (NYSDOH) Regional Offices, Local Health Departments

FROM: New York State Department of Health, Bureau of Healthcare Associated Infections

Informational Message:
Multistate *Burkholderia cepacia* Investigation – 2016

Please distribute immediately to: Hospital Epidemiologists, Infection Preventionists, Infectious Disease Physicians, Critical Care Medicine Physicians and Critical Care Staff, Pulmonologists, Medical Directors, Laboratory Directors, Pharmacy Directors, Nursing Directors and Risk Managers


Hospitals and other health care facilities are advised to monitor the CDC website frequently for new information and for any revisions or updates to CDC recommendations related to this outbreak.

Healthcare providers and laboratories should be on the alert for *B. cepacia* cases occurring among non-cystic fibrosis patients and should inform infection prevention staff when these infections occur. In addition, clusters of *B. cepacia* infections among patients with cystic fibrosis can be reported when infection rates appear above endemic rates. Cases that occur in NYSDOH licensed hospitals or other healthcare facilities licensed under Article 28 of the public health law should be reported to your NYSDOH regional epidemiologist or to the NYSDOH Central Office Bureau of Healthcare Associated Infections, Healthcare Epidemiology and Infection Control Program:

NYSDOH Regional and Central Office Contact Information:

- Western Regional Office (716) 847-4503
- Central New York Regional Office (315) 477-8166
- Metropolitan Area Regional Office (914) 654-7149
- Capital District Regional Office (518) 474-1142
- Central Office (518) 474-1142

Reporting requirements and instructions for NYSDOH facilities licensed under Article 28 of the Public Health Law are available at: [http://www.health.ny.gov/professionals/diseases/reporting/communicable/infection/reporting.htm](http://www.health.ny.gov/professionals/diseases/reporting/communicable/infection/reporting.htm)

General questions or comments about this advisory can be sent to icp@health.ny.gov.
Multistate Outbreak of *Burkholderia cepacia* Infections

**Update June 29, 2016**

Preliminary information continues to indicate that contaminated oral liquid docusate products might be related to *B. cepacia* complex infections in one state. At this time, there is no epidemiologic or laboratory evidence to suggest oral capsules or enemas are affected. Until more information is available, CDC continues to recommend that facilities not use any oral liquid docusate products for patients who are critically ill, ventilated, or immunosuppressed. Facilities that experience *B. cepacia* complex infections among non-cystic fibrosis patients or clusters of *B. cepacia* complex infections among cystic fibrosis patients should sequester all oral liquid docusate products.

Healthcare providers and laboratories should remain on alert for *B. cepacia* complex infections occurring among non-cystic fibrosis patients and should inform infection prevention staff when these infections occur. In addition, clusters of *B. cepacia* complex infections among patients with CF should be reported when infection rates appear above endemic rates. Cases should be reported to state or local public health authorities.

CDC will provide an update to this announcement by July 7. Please direct questions to CDC at haioutbreak@cdc.gov (mailto:haioutbreak@cdc.gov).

**Update June 24, 2016**

The Centers for Disease Control and Prevention (CDC) is collaborating with the Food and Drug Administration (FDA), multiple state and local health departments, and numerous healthcare facilities to investigate a multi-state outbreak of *Burkholderia cepacia* infections. These infections have occurred primarily in ventilated patients without cystic fibrosis and who are being treated in intensive care units.

Preliminary information indicates that a contaminated liquid docusate product might be related to cases in one state. Until more information is available, CDC recommends that facilities not use any liquid docusate products for patients who are critically ill, ventilated, or immunosuppressed. Institutions with non-cystic fibrosis patients in whom there are *B. cepacia* infections should sequester all liquid docusate products.

Healthcare providers and laboratories should be on alert for *B. cepacia* cases occurring among non-cystic fibrosis patients and should inform infection prevention staff when these infections occur. Cases should be reported to state or local public health authorities.

Please direct questions to CDC at haioutbreak@cdc.gov (mailto:haioutbreak@cdc.gov).